PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34125421-1	2021	BACKGROUND AND OBJECTIVES: Lisocabtagene maraleucel (liso-cel) is a CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	liso-cel	53-61	CD19 molecule	Homo sapiens	68-72	
34699774-1	2021	Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3zeta activatory domain connected to 4-1BB costimulatory domain.	liso-cel	26-34	CD19 molecule	Homo sapiens	53-57	
35156195-1	2022	Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor T-cell product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after 2 or more lines of systemic therapy.	liso-cel	26-34	CD19 molecule	Homo sapiens	54-58	
34030548-1	2021	INTRODUCTION: Lisocabtagene Maraleucel (Liso-cel) is a second-generation Chimeric Antigen Receptor T-cell (CAR-T) therapy product targeting CD19.	liso-cel	40-48	CD19 molecule	Homo sapiens	140-144	
35619325-1	2022	The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	liso-cel	99-107	CD19 molecule	Homo sapiens	20-24	
35610089-3	2022	Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, defined-composition, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	liso-cel	26-34	CD19 molecule	Homo sapiens	54-58